about
13C-urea breath test threshold calculation and evaluation for the detection of Helicobacter pylori infection in childrenEuropean Union Clinical Trials Register: on the way to more transparency of clinical trial data.Oculocutaneous albinism accompanied by minor morphologic stigmata and reduced number and function of NK cells. A new variant of NK cell defect?Results of the first randomized multicentre trial on childhood acute lymphoblastic leukaemia in Russia.Bridging the gap: a review of dose investigations in paediatric investigation plansRole of modeling and simulation in pediatric investigation plans.Changes and determination of dosing recommendations for medicinal products recently authorised in the European Union.Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology EuroImplementation of mechanism of action biology-driven early drug development for children with cancer.Cerebrospinal fluid soluble L-selectin (sCD62L) in meningoencephalitis.Secondary malignant neoplasms after intensive treatment of relapsed acute lymphoblastic leukaemia in childhood.Pharmacometrics for regulatory decision making: status and perspective.Quantification of cerebrospinal fluid proteins in children by high-resolution agarose gel electrophoresis.Quality management for clinical trials within the German Competence Network Paediatric Oncology and Haematology.Acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group (ALL-REZ BFM) experience: early treatment intensity makes the difference.Soluble l-selectin (sCD62L) in relapsed childhood acute lymphoblastic leukaemia.Preamble may not improve consent and assent processToo Few Medicines for Children With CancerQumquad: a UML-based approach for remodeling of legacy systems in health care[Pediatric hematology and oncology in Germany: On the verge of a new reimbursement system][Measures of quality assurance for in-patient pediatric oncology units][Quality management within the competence network of paediatric oncology and haematology]A meta-model of chemotherapy planning in the multi-hospital/multi-trial-center-environment of pediatric oncology[Assessment of staffing and infrastructures of paediatric oncology and haematology centres in Germany]Remodeling of legacy systems in health care using UML[Concepts of the Society of Paediatric Oncology and Haematology (GPOH) and the German Competence Network in Paediatric Oncology and Haematology for the quality controlled development in paediatric oncology][The "quality house pediatric oncology" as an instrument for improving the performance of the trial centers][Results of the Competence Net Pediatric Oncology and Haematology--a view back]A European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA)The European Medicines Agency: an overview of its mission, responsibilities, and recent initiatives in cancer drug regulationMedicines for pediatric oncology: can we overcome the failure to deliver?Revocation of the conditional marketing authorisation of a cancer medicine: The olaratumab experience
P50
Q24794113-6B1674C5-1FE5-4464-87D1-D8A5CD6D8C0EQ30663072-FC3F8E62-0B67-4CAD-9563-7A276E1B100BQ33378304-BAF3F62B-9FD2-4A77-B6C3-EC58A369C248Q33379080-2BB4BB79-EA02-410B-9EC8-AB2AEAD49469Q34554486-587BD005-5D1F-4738-88A4-73B950A3F645Q37829765-4F90854C-84CC-4CDA-8E7A-C557BFAC21D9Q38379186-62B786CB-A7D6-4DE3-9D3A-E6F1225EA77CQ38730798-0832E49A-F1A4-45B2-8B65-B38AACD88370Q38853019-7EB95EB0-B3E2-475A-9336-41543F77BED3Q40670445-C4936DA0-5EDE-4592-A8A7-D30C2D8EF568Q42521150-E3D85291-9CB5-4A2D-98BB-965A140660AAQ46966642-022D498E-6976-4778-824C-6C5A71916807Q48505757-74258D40-5865-4291-8D11-7FC4CC9F8E1FQ52938227-E2AB7711-3CA6-4DFE-8F52-436204A46B5EQ52946954-E782DF10-953D-48A5-B1A4-5D952DB2C585Q52954406-18809A10-BBB5-4C1E-A90E-0E5BC45AAF7FQ56777983-B3B663DD-4D8F-4591-99BA-BAD604D86B44Q57247143-43B60810-F7E6-4ADF-A9CB-AACE9C1BB631Q73789036-FC22BA51-9A05-4A2E-A9A3-E3BF69E626B4Q74583977-94358339-4835-48D7-BA97-A1872E31DA9BQ79323799-C4EB4F89-C4DD-4416-99D6-49BFEFE37480Q79368376-79188A64-4F71-49EA-BCDA-952838632F89Q80070356-CD1D9B53-52A0-445C-8D15-CA339F6C58B3Q80122972-2AA9EBD2-9277-4331-A785-0B4541A48723Q80813102-A5AE55DC-4C45-4437-B2D2-3751F854F7B9Q81061381-D20650D8-6AE3-41C2-A60E-8AD4222F1C62Q81695469-5D6E202A-EEEE-4280-80D3-DF761A9BAA17Q82354218-C5A953A5-04B1-4B23-8EB9-713F81B266B5Q82711948-E38203B1-DB54-4357-AD99-52B52D526196Q84770431-D027771F-85B7-4DD5-BAAD-8011FD8FE1B3Q85344832-1A0F000F-1DA8-437E-BA8F-0D12B1D0C6F4Q90956750-50398A51-9A66-4640-A95F-382F7B8E6DD8
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ralf Herold
@ast
Ralf Herold
@en
Ralf Herold
@es
Ralf Herold
@nl
Ralf Herold
@sl
type
label
Ralf Herold
@ast
Ralf Herold
@en
Ralf Herold
@es
Ralf Herold
@nl
Ralf Herold
@sl
prefLabel
Ralf Herold
@ast
Ralf Herold
@en
Ralf Herold
@es
Ralf Herold
@nl
Ralf Herold
@sl
P106
P21
P31
P496
0000-0002-8148-6748